Probable extinction of influenza B/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases.

Probable extinction of influenza B/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases.

Publication date: May 07, 2024

Early after the start of the COVID-19 pandemic, the detection of influenza B/Yamagata cases decreased globally. Given the potential public health implications of this decline, in this Review, we systematically analysed data on influenza B/Yamagata virus circulation (for 2020-23) from multiple complementary sources of information. We identified relevant articles published in PubMed and Embase, and data from the FluNet, Global Initiative on Sharing All Influenza Data, and GenBank databases, webpages of respiratory virus surveillance systems from countries worldwide, and the Global Influenza Hospital Surveillance Network. A progressive decline of influenza B/Yamagata detections was reported across all sources, in absolute terms (total number of cases), as positivity rate, and as a proportion of influenza B detections. Sporadically reported influenza B/Yamagata cases since March, 2020 were mostly vaccine-derived, attributed to data entry errors, or have yet to be definitively confirmed. The likelihood of extinction necessitates a rapid response in terms of reassessing the composition of influenza vaccines, enhanced surveillance for B/Yamagata, and a possible change in the biosafety level when handling B/Yamagata viruses in laboratories.

Open Access PDF

Concepts Keywords
Biosafety Databases
Covid Decline
Decreased Detections
Influenza Extinction
Global
Implications
Influenza
Probable
Public
Reported
Surveillance
Systematic
Virus
Yamagata

Semantics

Type Source Name
disease MESH influenza
disease MESH COVID-19 pandemic
disease VO vaccine
disease VO influenza vaccines
disease VO Viruses
disease MESH Infectious Diseases
disease VO Optaflu
disease MESH uncertainty
disease MESH infections
drug DRUGBANK Coenzyme M
disease VO vaccination
disease IDO replication
disease MESH secondary infections
disease IDO process
disease VO vaccine effectiveness
disease IDO country
pathway REACTOME Influenza Infection
disease VO Canada
disease VO USA

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *